$MCK

Lerman Bradley E sold $269K of MCK

Lerman Bradley E sold 301 shares of MCKESSON CORP (MCK) at $892.32 ($0.27M total) on 2026-08-10.

Original reporting
SEC EDGAR · Lerman Bradley E
Published Aug 11, 2026, 6:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 6:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
low confidence
Mentioned
$MCK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may marginally influence sentiment, but it does not introduce new operational or financial guidance.

02

Market read

Traders may note the insider sale, but there is no fundamental catalyst in the text to drive a durable repricing.

03

What to watch

Insider sales often have limited predictive value without accompanying changes in guidance, contracts, or governance actions; also, the director’s remaining holdings are reported as 0 shares, which may reflect a one-time liquidation rather than a trend.

Relevance 4/10Novelty 2/10Timing: filed 2026-08-11, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for McKesson, reported by a director.

Company-level read

Ticker impact

$MCKNeutralLow confidence
Context

McKesson Form 4 shows director Lerman Bradley E sold 301 shares on 2026-08-10 at $892.3250, exiting the position.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a Form 4 insider transaction, not earnings, guidance, or a corporate action. The article provides sale size and price but no new company-specific operating or regulatory development.

Market effects

None indicated; this is company-specific insider selling.

None indicated.

None indicated.

Counterpoint

The sale could be non-informational (taxes, diversification, or pre-planned liquidity), especially since the filing does not provide a 10b5-1 plan.

Key entities

  • MCK

    McKesson Corporation, the company whose insider transaction is disclosed.

  • Lerman Bradley E

    Director who sold 301 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

$MCKMedAI 8/10

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson (NYSE:MCK) to acquire Precision Medicine Group for $2.25B, expanding its oncology and specialty care business. The deal aims to enhance clinical research and commercialization services, with Precision Medicine joining McKesson's Oncology & Multispecialty segment. McKesson has been divesting non-core assets to fund such investments, and the Oncology segment saw 33% revenue growth in Q1 2026. However, the deal's timeline and integration risks remain uncertain.

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.